

DEA Places Ezogabine in Schedule V

The Drug Enforcement Administration (DEA) has issued a final rule to place Ezogabine into Schedule V of the Controlled Substance Act effective December 15, 2011.

Ezogabine is a new drug with a novel mechanism of action for the treatment of partial onset seizures. Because ezogabine is a new drug with possible immediate medical application to a lifethreatening illness not always treatable with medications currently available and because it may not be prescribed in the United States until this final rulemaking action is in effect and the subsequent requirements that result from this final action are satisfied, the Administrator hereby finds that it is in the interest of public health to forego the 30 day period prior to this final rule taking effect. This will impose no hardship on any interested party and is responsive to comments intended to facilitate the availability of ezogabine as soon as possible for that population of people suffering from seizures that may benefit from treatment with ezogabine. Therefore, in accordance with this finding of conditions of public health and of good cause to waive the 30 day period and pursuant to 21 CFR 1308.45 and 5 U.S.C. 553(d)(3), this final rule is effective upon publication.

Upon the effective date of this final rule, ezogabine is subject to the CSA regulatory controls and administrative, civil and criminal sanctions applicable to the manufacture, distribution, dispensing, importing and exporting of a Schedule V controlled substance. The Federal Register Notice is found [here](#).

ONDCP To Host Conference Call on Synthetic Drug Use Dec. 19, 2011

On Monday, December 19, 2011 the Office of National Drug Control Policy (ONDCP) and the American Public Health Association (APHA) will be hosting a conference call to discuss Federal, State, and local efforts to address the rising public health and safety threat of synthetic drug use, including Spice, K2, and "Bath salts."

The ONDCP/APHA Synthetic Drug Conference Call will feature the latest data available on synthetics from the 2011 Monitoring the Future survey, provide an opportunity to discuss challenges in dealing with this public health threat. You can read more about Monitoring the Future and synthetics on the [ONDCP Blog](#).

**Happy
Holidays**

**NASCSA
wishes
everyone a
happy and
healthy
holiday
season!**

Speakers will include:

* Gil Kerlikowske, Director, Office of National Drug Control Policy

* J. Alan Baker, Interim Executive Director, American Public Health Association

* Cara Smith, Deputy Chief of Staff, Office of Illinois Attorney General Lisa Madigan

The call will conclude with an opportunity for participants to ask questions to our speakers and topic experts including ONDCP Deputy Directors David Mineta and Ben Tucker.

Monday, December 19, 2012

3:30 - 4:30 pm eastern

Conference Number: 1-866-710-0179

Conference Code: 7166

Please contact Jacqueline Hackett (JHackett@ondcp.eop.gov) with any questions. We look forward to your participation in his important conversation. There are a limited number of phone lines available for this call.

Reminder - 2012 Prescription Drug Monitoring Program Grant Deadline is January 6, 2012

States are reminded that the deadline for applying for Prescription Drug Monitoring Program (PDMP) grants administered by The National Association of State Controlled Substances Authorities (NASCSA) for FY2012 is **January 6, 2012 at 5 p.m. Pacific Time.**

Funding provided by Purdue Pharma, LLP is designed to assist states with funding (PDMPs) for the purpose of operating and expanding such programs, and promoting the ability of state PDMPs to address the abuse and diversion of controlled substances through education. The Executive Committee will solely be responsible for the selection of grant recipients and the determination of award amounts.

The maximum amount of each grant is \$20,000, unless special circumstances warrant awarding a grant in an amount in excess of \$20,000. Smaller projects costing \$5,000 - \$10,000 each are also encouraged.

For a complete set of criteria go to: **[NASCSA's website.](#)**